Search found 531 matches
- Tue May 25, 2021 4:30 pm
- Forum: ImetelChat
- Topic: The way forward
- Replies: 7
- Views: 5103
Re: The way forward
Dear members, As Huntingonthebluffs suggested, I created a Gofundme campaign in order to keep this website going: https://gofund.me/953c30c3. You are more than welcome to donate any amount there. Together we'll be able to finance hosting, domain name and maintenance of ImetelChat/Imetelstat.eu. The ...
- Tue May 25, 2021 1:12 pm
- Forum: ImetelChat
- Topic: The way forward
- Replies: 7
- Views: 5103
The way forward
Dear members, Thanks to everyone who reached out to me. It helped me understand how much this board means to you. Combined with your pledges for support, this made me decide to keep ImetelChat in the air at least until we've figured out a way to keep this community alive. In a practical sense the fu...
- Tue Jul 24, 2018 3:15 pm
- Forum: ImetelChat
- Topic: New members can register again!
- Replies: 5
- Views: 36257
New members can register again!
Hi all,
Due to some technical difficulties new members were unable to sign up for a while. I'm glad to announce this problem has been solved!
New members are once again welcome to register.
Regards,
Fish Jr.
Due to some technical difficulties new members were unable to sign up for a while. I'm glad to announce this problem has been solved!
New members are once again welcome to register.
Regards,
Fish Jr.
- Tue Jul 24, 2018 3:07 pm
- Forum: ImetelChat
- Topic: General Announcement from bio pearl
- Replies: 6
- Views: 40892
Re: General Announcement from biopearl
All,
I'd like to officially welcome Biopearl as Global Administrator!
I'm convinced that with his knowledge and dedication Biopearl will do a great job maintaining the high quality standard of discussion/content on this website.
Kind regards,
Fish Jr.
I'd like to officially welcome Biopearl as Global Administrator!
I'm convinced that with his knowledge and dedication Biopearl will do a great job maintaining the high quality standard of discussion/content on this website.
Kind regards,
Fish Jr.
- Wed Jun 13, 2018 2:10 pm
- Forum: ImetelChat
- Topic: Goodbye
- Replies: 9
- Views: 13358
Re: Goodbye
As to the future of Imetelstat.eu/ImetelChat: still unclear, will keep you posted.
- Wed Jun 13, 2018 1:49 pm
- Forum: ImetelChat
- Topic: Goodbye
- Replies: 9
- Views: 13358
Goodbye
Dear reader, It is with great sadness that I announce the passing of my father and founder of this website, Fishermangents. He gave me his username and password before he died, as he became too weak to contribute in any way. "Fish" suffered from Myelofibrosis (MF) for which he received a stem cell t...
- Mon Apr 16, 2018 3:37 am
- Forum: ImetelChat
- Topic: (08-02-2018) - Janssen BioTech applies for global patent for combo treatment for hematologic cancers, incl imetelstat
- Replies: 5
- Views: 11493
- Sun Apr 15, 2018 11:11 pm
- Forum: ImetelChat
- Topic: (08-02-2018) - Janssen BioTech applies for global patent for combo treatment for hematologic cancers, incl imetelstat
- Replies: 5
- Views: 11493
Re: (08-02-2018) - Janssen BioTech applies for global patent for combo treatment for hematologic cancers, incl imetelsta
Great comments, thanks. For now I would stIck to hematolgic cancers and leave solid tumors aside. This patent is limited to that for very good and well researched reasons (medical, business), as we may expect from a partner like JnJ. It is this focus that adds to its strength.
- Sat Apr 14, 2018 8:46 pm
- Forum: ImetelChat
- Topic: (08-02-2018) - Janssen BioTech applies for global patent for combo treatment for hematologic cancers, incl imetelstat
- Replies: 5
- Views: 11493
(08-02-2018) - Janssen BioTech applies for global patent for combo treatment for hematologic cancers, incl imetelstat
(08-02-2018) - Janssen BioTech applies for global patent for COMBINATION TREATMENT FOR HEMATOLOGICAL CANCERS, including Imetelstat. The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are...
- Tue Mar 27, 2018 12:35 pm
- Forum: ImetelChat
- Topic: Link to recent article on pancreatic cancer cell lines
- Replies: 2
- Views: 4836
Re: Link to recent article on pancreatic cancer cell lines
Is on Imetelstat.info/pre-clinical Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells K.M. Burchett et al (2017) Imetelstat (GRN163L) is a potent and selective inhibitor of telomerase. We have previously reported that GRN163L could sh...
- Tue Mar 27, 2018 12:30 pm
- Forum: ImetelChat
- Topic: Response to Sargasso (thanks for the great articles)
- Replies: 1
- Views: 4033
Re: Response to Sargasso (thanks for the great articles)
Can't agree more!
- Tue Mar 27, 2018 12:29 pm
- Forum: ImetelChat
- Topic: Geron to present at 17th Needham Healthcare Conference on March 27, 2018
- Replies: 5
- Views: 8544
Re: Geron to present at 17th Needham Healthcare Conference on March 27, 2018
Difficult to say; I am not expecting real new things and I do believe known things to be confirmed. So in my opinion there is a good change of GERN going up further or there will be little profit taking. Both, on the longer term, are not that significant, so taking the momentum and setting aside som...
- Fri Mar 23, 2018 11:31 pm
- Forum: ImetelChat
- Topic: Continuation of excellent posts by Sdraw on YMB
- Replies: 5
- Views: 6995
Re: Continuation of excellent posts by Sdraw on YMB
Yes, it does!
- Fri Mar 23, 2018 10:07 am
- Forum: ImetelChat
- Topic: Geron to present at 17th Needham Healthcare Conference on March 27, 2018
- Replies: 5
- Views: 8544
Geron to present at 17th Needham Healthcare Conference on March 27, 2018
MENLO PARK, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference in New York at 4:00 p.m. Eastern Time on Tuesday, March 27, 201...
- Thu Mar 22, 2018 9:12 pm
- Forum: ImetelChat
- Topic: Concerning anonymous short sellers
- Replies: 5
- Views: 7993
Re: Concerning anonymous short sellers
One of the measures a company can take is making sure that there is enough cash on board to bridge to success. So far Geron has anticipated to that. Suing manipulative short attacks is risky, as the shorters may use that to prove there is really something wrong. However, SEC should be able to step u...
- Thu Mar 22, 2018 10:33 am
- Forum: ImetelChat
- Topic: How to join this board
- Replies: 2
- Views: 5521
Re: How to join this board
As you may have noticed the registration functionality is not activated. To become member please send an email to info@imetelstat.eu, mentioning your preferred username and valid email address. I will then contact you with your credentials.
- Thu Mar 22, 2018 10:23 am
- Forum: ImetelChat
- Topic: In case Sdraw reads this board--repost from SA
- Replies: 3
- Views: 5247
Re: In case Sdraw reads this board--repost from SA
the Gupta PNAS article is great. Will add it to imetelstat.info soon.
- Wed Mar 21, 2018 8:24 pm
- Forum: ImetelChat
- Topic: General Announcement--Assistant Moderator
- Replies: 1
- Views: 3611
Re: General Announcement--Assistant Moderator
Dear bio, I am honored and happy that you took up this role with me. Lets keep building this board into a concise and serious meetingplace for all those interested in telomerase, TI, imetelstat and Geron/JnJ.
- Wed Mar 21, 2018 3:56 pm
- Forum: ImetelChat
- Topic: EMA Prime
- Replies: 4
- Views: 8655
Re: EMA Prime
If Median OS is not reached, that is good. In order to put the survivors into the perspective it is important how these survivors are doing, why they survive, even after Median OS has been achieved. That will give additional weight to the benefits and to see the depth of PR's and CR's and the target...
- Wed Mar 21, 2018 3:46 pm
- Forum: ImetelChat
- Topic: OS vs median OS
- Replies: 1
- Views: 4277
Re: OS vs median OS
Wikipedia: 'Median survival, or "median overall survival" is also commonly used to express survival rates. This is the amount of time after which 50% of the patients have died and 50% have survived. In ongoing settings such as clinical trials, the median has the advantage that it can be calculated o...